A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications

Seasonal influenza is responsible for many hospitalizations and deaths each year, despite effective antiviral treatments. Some individuals have medical conditions such as heart or lung diseases that make them particularly at risk of severe influenza infections that may result in hospitalization or death. Oseltamivir (Tamiflu) is used most often to treat flu, but there are still many hospitalizations, complications, and deaths even with treatment. This study evaluated the use of combination antivirals (amantadine, oseltamivir, and ribavirin) compared to oseltamivir alone in the treatment of influenza in an at-risk population.

开始日期2010-09-01

申办/合作机构

National Institute of Allergy & Infectious Diseases

NCT00979251 / Completed临床2期

A Randomized Open Label Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Amantadine and Ribavirin With Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immunocompromised Subjects

This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment of all strains of influenza A in immunocompromised adult and pediatric subjects.

开始日期2009-09-01

申办/合作机构

Adamas Pharmaceuticals LLC

NCT00867139 / Completed临床1/2期IIT

A Pilot, Randomized Study Comparing the Safety, Tolerability and Pharmacokinetics of Combination Therapy (Amantadine, Ribavirin, Oseltamivir) Versus Neuraminidase Inhibitor Monotherapy to Influenza Virus Infected Immunocompromised Patients

The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD

开始日期2009-03-01

申办/合作机构

Fred Hutchinson Cancer Research Center

100 项与金刚烷胺/奥司他韦/利巴韦林相关的临床结果

登录后查看更多信息

100 项与金刚烷胺/奥司他韦/利巴韦林相关的转化医学

登录后查看更多信息

100 项与金刚烷胺/奥司他韦/利巴韦林相关的专利（医药）

登录后查看更多信息

100 项与金刚烷胺/奥司他韦/利巴韦林相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
甲型流感病毒感染	临床3期	美国	Adamas Pharmaceuticals LLC	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01227967 (IRC003, CTgov)	临床2期	流感病毒感染	881	Amantadine, Ribavirin, Oseltamivir (Combination Therapy)	壓鹹醖築夢廠網鹹願壓(廠遞顧簾遞膚簾繭壓醖) = 製願蓋鏇夢鹽構積鹹鬱獵鹹顧糧廠築壓網製廠 (遞鑰選鏇淵遞築艱衊鑰, 鏇鑰願蓋襯鹽積齋齋夢 ~ 淵鏇齋獵壓醖餘壓網遞) 更多	-	2017-07-11
				oseltamivir (Oseltamivir Monotherapy)	壓鹹醖築夢廠網鹹願壓(廠遞顧簾遞膚簾繭壓醖) = 鹹選繭顧獵蓋獵選顧襯獵鹹顧糧廠築壓網製廠 (遞鑰選鏇淵遞築艱衊鑰, 廠顧淵淵蓋壓獵醖鹹衊 ~ 觸網衊築鏇餘膚築膚鏇) 更多
NCT00867139 (CTgov)	临床1/2期	甲型流感病毒感染	7	oseltamivir+ribavirin+amantadine (TCAD)	獵憲糧鏇壓夢鑰鑰選醖(艱獵顧壓範積選壓構網) = 網構遞鑰觸齋鹽鑰夢壓衊艱遞壓艱繭衊鬱鑰淵 (夢願簾願繭繭糧鏇壓鹽, 淵醖鹽選廠積憲遞餘鏇 ~ 繭製鑰餘選獵齋鏇餘齋) 更多	-	2013-06-04
				Inihibitor (Neuraminidase Inihibitor Monotherapy)	獵憲糧鏇壓夢鑰鑰選醖(艱獵顧壓範積選壓構網) = 製餘廠襯顧糧鏇鏇獵觸衊艱遞壓艱繭衊鬱鑰淵 (夢願簾願繭繭糧鏇壓鹽, 壓願製醖積糧網積觸構 ~ 積窪網製顧齋艱蓋製簾) 更多